Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
Metrics to compare | TTNP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTTNPPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −1.8x | −0.6x | |
PEG Ratio | −0.02 | −0.02 | 0.00 | |
Price / Book | 1.1x | 2.3x | 2.6x | |
Price / LTM Sales | 1,432.3x | 1.5x | 3.2x | |
Upside (Analyst Target) | - | 210.8% | 49.1% | |
Fair Value Upside | Unlock | 5.2% | 7.2% | Unlock |